FDA response letter News
Most Popular FDA response letter Story
FDA rejects Yondelis-Doxil combo for ovarian cancer
The FDA has rejected Centecor Ortho Biotech's application to market Doxil in combination with Zeltia's Yondelis (trabectedin) as a treatment for ovarian cancer. Following a panel recommendation Read more...
Latest Headlines
- August 29, 2011
- April 18, 2011
- October 28, 2010
- October 24, 2010
- October 20, 2010
- March 29, 2010
- February 18, 2010
- January 29, 2010
- December 31, 2009
- December 10, 2009
- December 7, 2009
- September 10, 2009
- August 3, 2009
- July 6, 2009
- July 2, 2009
- June 26, 2009
- June 24, 2009
- January 20, 2009
- January 14, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
